Compare TWN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TWN | BWAY |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.0M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | TWN | BWAY |
|---|---|---|
| Price | $57.14 | $16.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | 20.1K | ★ 61.3K |
| Earning Date | 01-01-0001 | 11-11-2025 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $53.28 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $25.22 | $7.84 |
| 52 Week High | $41.51 | $18.18 |
| Indicator | TWN | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 46.21 |
| Support Level | $56.65 | $16.75 |
| Resistance Level | $58.67 | $17.38 |
| Average True Range (ATR) | 1.25 | 0.75 |
| MACD | 0.17 | -0.07 |
| Stochastic Oscillator | 57.64 | 21.06 |
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.